On June 28, 2022 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, reported the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-6236, the company’s oral, potent, tri-complex RAS(ON) Inhibitor designed to treat patients with cancers driven by a variety of RAS mutations (Press release, Revolution Medicines, JUN 28, 2022, View Source [SID1234616317]). RMC-6236, which the company refers to as a RASMULTI (ON) Inhibitor, is the first development candidate from Revolution Medicines’ portfolio of novel RAS(ON) Inhibitors to enter clinical development.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Phase 1/1b trial (NCT05379985) is a multicenter, open-label, dose-escalation and dose-expansion study of RMC-6236 in patients with advanced solid tumors harboring selected KRASG12 mutations, including KRASG12D, KRASG12V and KRASG12R. The primary objectives of the study are to evaluate safety and tolerability and to inform the recommended Phase 2 dose and schedule (RP2DS) for the compound. The study’s first patient has pancreatic cancer with a KRASG12D mutation, the most common genetic variant of RAS proteins causing cancer.
"Beginning clinical evaluation of the first compound from our broad portfolio of RAS(ON) Inhibitors marks a significant milestone in our efforts to serve unmet needs of patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "To our knowledge, RMC-6236 is the first oral, direct RAS inhibitor to be deployed against a tumor harboring the KRASG12D variant, and it ushers in a wave of groundbreaking RAS(ON) Inhibitors we expect to advance."
Steve Kelsey, M.D., president, research and development at Revolution Medicines said, "RMC-6236 is a compelling drug candidate with the potential to demonstrate broad utility across many RAS cancer variants, particularly those harboring KRASG12 mutations. We are enthusiastic about its potential both to display first-in-class single agent activity as an inhibitor of mutant RAS and to be deployed as a RAS Companion Inhibitor in combination with mutant-selective RAS(ON) Inhibitors we have in development."
The company also highlights the election of Sushil Patel, Ph.D., to its board of directors at its recent annual meeting of stockholders. Dr. Patel has more than twenty years of experience in the biotech industry, focused on commercialization strategy and execution in U.S. and global oncology markets. He currently serves as chief commercial officer of Replimune Group, a clinical-stage biotechnology company developing novel tumor-directed oncolytic immunotherapies. Previously, Dr. Patel held various positions at Genentech, Inc., where he served as franchise head for lung, skin, and rare cancers that included several blockbuster products in both targeted therapies and immuno-oncology. Notably, he led lifecycle management of Tecentriq (atezolizumab) in lung cancer and helped lead more than eight product launches across more than twenty different indications. Dr. Patel holds a Ph.D. in molecular biology from the University of London and a Master’s degree in biotechnology from the Imperial College London.
Dr. Goldsmith added, "We are very fortunate to have Sushil join our board of directors. His commercial expertise in bringing innovative cancer drugs to patients will provide a valuable perspective as we advance our deep product pipeline."